NYU Langone has raised over $10 million to help advance the establishment of a one-of-a-kind center that will expand research and physician training in the resurging field of psychedelic medicine. This novel new center called the Center for Psychedelic Medicine includes the Psychedelic Medicine Research Training Program—which differentiates this center from others—and will support the development of early career faculty members and postdoctoral fellows to become independent investigators in the field of psychedelic medicine. When fully ramped up, the center will operate under NYU Langone’s Department of Psychiatry and will support health-focused research across the translational spectrum, from basic science to Phase 3 clinical trials. The group will run three transdisciplinary segments, including 1) psychiatry, 2) medicine, and 3) preclinical research.
MindMed, a neuropharmaceutical company, has invested $5 million in the center to help support its efforts to pioneer new ways to treat mental health disorders via the advancement of both non-hallucinogenic and hallucinogenic compounds. The funds will contribute directly to a psychedelic-based training progra...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).